Officers raided an address in the Llanrwst area following reports that prescription weight-loss drugs were being sold without ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

A spokesperson for Novo Nordisk, the manufacturer of Wegovy, said: “Wegovy is indicated for weight management, including ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...